What should I know first?

Memantine affects a receptor/channel called NMDA, which participates in glutamate signaling. Glutamate is a chemical messenger used widely in the nervous system.

This example covers U.S. immediate-release memantine hydrochloride tablets for moderate to severe dementia of the Alzheimer’s type. It does not extend that use to every memory difficulty or to all medicines affecting NMDA receptors.

This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.

How Brain Cells Communicate

NMDA is one type of receptor that responds within glutamate signaling. It also forms a channel through which positively charged ions can move when the activation conditions are met.

Glutamate signaling has normal functions. It should not be described as a toxin that the brain needs to remove completely. A single messenger is not a complete explanation of Alzheimer’s disease.

An open NMDA-receptor channel with agonist symbols outside and sodium/calcium ion symbols in a pore. Activation requirements are simplified. Sodium / calcium · Na⁺ / Ca²⁺: This example shows inward movement of positively charged ions. NMDA glutamate receptor / channel: The pore opens under appropriate activation conditions. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.
  1. Sodium / calcium · Na⁺ / Ca²⁺

    This example shows inward movement of positively charged ions.

  2. NMDA glutamate receptor / channel

    The pore opens under appropriate activation conditions.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Qualitative NMDA channel model, not atomic geometry. Target action is not evidence of slowing neurodegeneration.
About this illustration

Under the appropriate activation conditions, an NMDA receptor channel permits positively charged ions to pass. The arrow shows a teaching example of inward current.

How the Medication Changes Signaling

Memantine is an uncompetitive, open-channel NMDA receptor antagonist. In plain language, its blocking action is associated with channels that have opened. It can limit current through these channels.

The bar on the diagram means reduced passage in this teaching model. It is not a measured atomic site, a permanently sealed channel, or a command to eliminate all NMDA activity.

Explore the mechanism

What does open-channel antagonism mean?

An open NMDA-receptor channel with agonist symbols outside and sodium/calcium ion symbols in a pore. Activation requirements are simplified. Sodium / calcium · Na⁺ / Ca²⁺: This example shows inward movement of positively charged ions. NMDA glutamate receptor / channel: The pore opens under appropriate activation conditions. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.
  1. Sodium / calcium · Na⁺ / Ca²⁺

    This example shows inward movement of positively charged ions.

  2. NMDA glutamate receptor / channel

    The pore opens under appropriate activation conditions.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Static introduction. Qualitative NMDA channel model, not atomic geometry. Target action is not evidence of slowing neurodegeneration.
An open NMDA-receptor channel with agonist symbols outside and sodium/calcium ion symbols in a pore. Activation requirements are simplified. Sodium / calcium · Na⁺ / Ca²⁺: This example shows inward movement of positively charged ions. NMDA glutamate receptor / channel: The pore opens under appropriate activation conditions. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.
  1. Sodium / calcium · Na⁺ / Ca²⁺

    This example shows inward movement of positively charged ions.

  2. NMDA glutamate receptor / channel

    The pore opens under appropriate activation conditions.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Before medicine: an open channelUnder the appropriate activation conditions, an NMDA receptor channel permits positively charged ions to pass. The arrow shows a teaching example of inward current.
An NMDA receptor with an open outer pore and a terracotta medicine symbol within the pore, illustrating open-channel block. Sodium / calcium · Na⁺ / Ca²⁺: This example shows inward movement of positively charged ions. NMDA glutamate receptor / channel: The pore opens under appropriate activation conditions. Memantine: open-channel block: The medicine symbol labels an action, not an experimentally determined binding position.
  1. Sodium / calcium · Na⁺ / Ca²⁺

    This example shows inward movement of positively charged ions.

  2. NMDA glutamate receptor / channel

    The pore opens under appropriate activation conditions.

  3. Memantine: open-channel block

    The medicine symbol labels an action, not an experimentally determined binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

With memantineMemantine’s action is described as open-channel antagonism. The crossbar marks reduced current in the schematic, not an experimentally verified position or permanent closure.

What this model cannot tell us

Not proof of disease slowing

  • Not proof of disease slowing The clinical explanation remains uncertain.
  • Limits of inference An experimental result does not by itself predict one person’s treatment response.
Symptom treatment has limitsThe product label does not establish prevention or slowing of the underlying degeneration. A target effect does not guarantee a particular clinical response.

Static overview. Start the steps when you are ready.

Guide to the illustration: Outlines identify a cell membrane or target; arrows mark the direction explained in each caption. Medicine symbols are labels, not measured shapes or binding poses. No quantity, size or rate is to scale.

Read the complete sequence
  1. Before medicine: an open channel. Under the appropriate activation conditions, an NMDA receptor channel permits positively charged ions to pass. The arrow shows a teaching example of inward current.
  2. With memantine. Memantine’s action is described as open-channel antagonism. The crossbar marks reduced current in the schematic, not an experimentally verified position or permanent closure.
  3. Symptom treatment has limits. The product label does not establish prevention or slowing of the underlying degeneration. A target effect does not guarantee a particular clinical response.
Evidence and model limits

Current generic tablet record reconciled with reference-product FDA labeling. The original Namenda brand tablets are discontinued in the FDA product record; this lesson does not claim current brand availability.

Qualitative NMDA channel model, not atomic geometry. Target action is not evidence of slowing neurodegeneration.

A Closer Look at the Molecular Level

Known action: open-channel antagonism is described in the labeling. Persistent NMDA activation has been proposed as a contributor to symptoms, but a proposed disease mechanism is not the same as an established cause in one person.

Clinical limitation: the label does not establish that memantine prevents or slows the underlying nerve-cell degeneration in Alzheimer’s disease. A channel effect must not be presented as a cure or a guarantee of benefit.

Sources and References

The sources below support the specific medicine and experimental context described here. Drawings are original qualitative teaching models; positions, arrows and timing do not give atomic geometry, occupancy or rates.

  1. DailyMed: memantine hydrochloride tablets, updated March2026
  2. FDA: Namenda reference-product label
  3. NIH: What Is a Neurotransmitter?

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top